Hospital

The drug is the first approved antiviral COVID-19 treatment that could be used across all stages of liver disease.

Belzutifan also demonstrated statistically significant improvements in objective response rate compared to everolimus for advanced renal cell carcinoma.

In the study, investigators incorporated data from electronic health records and social determinants of health into the model to determine the likelihood in delays when starting cancer therapy.

Notably, 65% of the participants experiencing pain at the 2-month follow up were also experiencing pain at their 12-month follow up, suggesting persistent and long-term pain.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Protection of T cells from tumor-induced suppression suggests potential for enhancing efficacy of therapies, with plans to initiate a phase 1/2 clinical trial in patients with advanced breast cancer.

The drug showed statistically significant and clinically meaningful efficacy results across key subgroups.

Patients with pancreatic cancer who took benzodiazepine lorazepam had a shorter progression-free survival than those who took benzodiazepine alprazolam.

Relapses of MIS-C occurred in 2 patients due to rapid tapering of corticosteroids at 2 weeks instead of the standard protocol of 4 to 6 weeks.

Researchers sought to find a remedy for the development of treatment-resistant depression in patients whose antidepressant treatment has fluctuated in efficacy.

The treatment is the first of its kind to be FDA-approved to treat CHAPLE disease.

The model was the first to incorporate C-reactive protein/albumin ratio and apply LASSO regression analysis to a predictive model for children with Kawasaki disease.

The results differ from previous studies and the predictions of the researchers that the Child Tax Credit would reduce the prevalence of low birth weight among pregnant women across the country.

Opportunities for an additional specialization in molecular pathology may be helpful to train professionals in the real-time interpretation of gene therapy test results.

Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.

The approach allows investigators to assess post-vaccine response in immunocompromised patients who have received antibody prophylaxis.

Previous studies have shown promising results with liver or kidney transplants in patients with HIV, but there was a lack of literature regarding heart transplants specifically.

Although the rate of people with probable insomnia who discussed their sleep habits with a physician was relatively high, the number of people who went on to seek actual treatment was low.

Annual NCODA Oncology Institute brings together leaders in industry to speak with leaders in clinical practice to discuss some of the commonalities and areas of opportunity to address challenges facing oncology professionals.

Adjustments for social determinants of health in the US population had a significant impact on cardiovascular disease mortality data between Black and White populations.

The findings of the study demonstrate the need for preventive interventions for all infants in order to reduce the burden of severe illness from respiratory syncytial virus lower respiratory tract infections.

A COVID-19 booster dose increased both maternal and cord blood binding and neutralizing antibody levels against virus strains, including Omicron BA.1.

The Mylight phase 3 trial confirmed that there was no clinically meaningful differences between aflibercept and its reference biologic, Eylea, for patients with wet macular degeneration.

The combination regimen showed positive progression-free survival results among patients with HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, but overall survival data have yet to mature.

Researchers recommended less restrictive policy regarding telepharmacies to improve access to medications and pharmacists, while ultimately improving outcomes and adherence to treatment regimens.

Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.

Topics discussed include care workflow, app functionalities, problems and disadvantages, and benefits for HIV experts.

Pharmacies brace for a double wave of DIR fees while paddling against profit struggles. Enter Pharmacy AI: a transformative vehicle to navigate stormy waters, enhance efficiency, and prioritize patient care.